| Index | — | P/E | — | EPS (ttm) | -3.82 | Insider Own | 8.89% | Shs Outstand | 141.01M | Perf Week | -28.57% |
| Market Cap | 296.12M | Forward P/E | — | EPS next Y | -0.76 | Insider Trans | -0.32% | Shs Float | 109.88M | Perf Month | -22.79% |
| Enterprise Value | 10.35B | PEG | — | EPS next Q | -0.24 | Short Float | 11.19% | Perf Quarter | -29.05% | ||
| Income | -516.00M | P/S | 0.01 | EPS this Y | -234.00% | Short Ratio | 8.79 | Perf Half Y | -26.32% | ||
| Sales | 22.08B | P/B | — | EPS next Y | — | ROA | -4.26% | Short Interest | 12.30M | Perf YTD | -32.69% |
| Book/sh | -6.64 | P/C | 1.91 | EPS next 5Y | — | ROE | — | 52W High | 4.20 -50.00% | Perf Year | -49.15% |
| Cash/sh | 1.10 | P/FCF | — | EPS past 3/5Y | 120.85% -2.95% | ROIC | -85.85% | 52W Low | 2.09 0.48% | Perf 3Y | -11.76% |
| Dividend Est. | — | EV/EBITDA | 2.27 | Sales past 3/5Y | 0.74% 1.15% | Gross Margin | 47.77% | Volatility | 9.35% 5.08% | Perf 5Y | -80.52% |
| Dividend TTM | — | EV/Sales | 0.47 | EPS Y/Y TTM | -257.71% | Oper. Margin | -39.67% | ATR (14) | 0.16 | Perf 10Y | -79.75% |
| Dividend Ex-Date | Dec 13, 2012 | Quick Ratio | 1.48 | Sales Y/Y TTM | 74.65% | Profit Margin | -2.34% | RSI (14) | 22.18 | Recom | 3.03 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.48 | EPS Q/Q | -137.80% | SMA20 | -24.08% | Beta | 1.85 | Target Price | 2.94 |
| Payout | 0.00% | Debt/Eq | — | Sales Q/Q | -10.69% | SMA50 | -26.34% | Rel Volume | 2.45 | Prev Close | 2.40 |
| Employees | 50,500 | LT Debt/Eq | — | Earnings | Feb 17 | SMA200 | -30.60% | Avg Volume | 1.32M | Price | 2.10 |
| IPO Date | Jun 09, 2000 | Option/Short | No / Yes | EPS/Sales Surpr. | -63.52% -1.58% | Net Debt/EBITDA | 2.21 | Volume | 3,223,383 | Change | -12.50% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-22-26 | Reiterated | BMO Capital | Market Perform | $3.00 |
| Jul-27-26 | Reiterated | Truist Securities | Hold | $3.75 → $3.25 |
| Jul-24-26 | Reiterated | UBS | Neutral | $3.70 → $3.00 |
| Jul-23-26 | Reiterated | Barclays | Underweight | $3.00 → $2.50 |
| Jul-14-26 | Reiterated | Truist Securities | Hold | $3.00 → $3.75 |
| Jul-08-26 | Downgrade | Barclays | Equal Weight → Underweight | |
| Apr-23-26 | Reiterated | Barclays | Equal Weight | $3.00 |
| Apr-23-26 | Reiterated | Truist Securities | Hold | $4.50 → $3.00 |
| Feb-20-26 | Reiterated | UBS | Neutral | $3.60 → $3.70 |
| Jan-07-26 | Reiterated | Wells Fargo | Underweight | $3.00 → $2.00 |
Community Health Systems, Inc. (CYH) operates as a major healthcare provider across the United States, focusing on the ownership, leasing, and management of general acute care hospitals. The organization offers a comprehensive array of medical services, including emergency care, general and specialized surgical procedures, critical care, internal medicine, obstetrics, and various diagnostic capabilities. Additionally, they provide psychiatric services, rehabilitation programs, skilled nursing, and in-home care. Beyond its hospital-based offerings, the company delivers outpatient services through a diverse network of facilities. These encompass primary care practices, urgent care centers, independent emergency departments, ambulatory surgery centers, advanced imaging and diagnostic centers, retail health clinics, and direct-to-consumer virtual health consultations. As of December 31, 2021, CYH's holdings included 83 hospitals, either owned or leased. This total comprised 81 general acute care facilities and two specialized stand-alone rehabilitation or psychiatric hospitals, collectively providing a capacity of 13,289 licensed patient beds. The company was established in 1985 and its corporate headquarters are situated in Franklin, Tennessee.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 22,083 | 12,485 | 12,634 | 12,490 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 11,533 | 11,403 | 7,364 | 7,408 | — | — | — | — | — | |
| Gross Profit | 10,550 | 1,082 | 5,270 | 5,082 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 10,364 | 0 | 299 | 319 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 80 | — | — | — | — | — | |
| Other Operating Expense | 11,558 | 10,997 | 4,429 | 3,726 | — | — | — | — | — | |
| Operating Income | -8,761 | -9,915 | 542 | 957 | — | — | — | — | — | |
| Interest Expense | 841 | 870 | 863 | 832 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 9,070 | 11,509 | 38 | 82 | — | — | — | — | — | |
| Net Income Before Taxes | -532 | 724 | -283 | 207 | — | — | — | — | — | |
| Income Taxes | 236 | 48 | 79 | 191 | — | — | — | — | — | |
| Consolidated Net Income | -516 | 509 | -516 | -133 | — | — | — | — | — | |
| Net Income From Continuing Operations | -768 | 676 | -362 | 16 | — | — | — | — | — | |
| Net Income | -516 | 509 | -516 | -133 | — | — | — | — | — | |
| EPS (Recurring) | -3.86 | 3.80 | -3.90 | -1.02 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.86 | 3.80 | -3.90 | -1.02 | — | — | — | — | — | |
| EPS (Diluted) | -3.82 | 3.77 | -3.90 | -1.02 | — | — | — | — | — | |
| EBITDA | 4,554 | 2,020 | 1,329 | 1,375 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | 0.83 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.01 | 0.03 | 0.03 | 0.03 | — | — | — | — | — | |
| Gross Margin | 47.77 | 8.67 | 41.71 | 40.69 | — | — | — | — | — | |
| Operating Margin | -39.67 | -79.42 | 4.29 | 7.66 | — | — | — | — | — | |
| Net Margin | -2.34 | 4.08 | -4.08 | -1.06 | — | — | — | — | — | |
| Shares Outstanding | 136 | 134 | 132 | 130 | — | — | — | — | — | |
| Market Capitalization | 286 | 418 | 395 | 407 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| JENNINGS WILLIAM NORRIS | Director | Aug 25 '26 | Sale | 2.96 | 40,000 | 118,400 | 38,468 | Aug 25 |
| Krishnan K Ranga | Director | Jun 30 '26 | Option Exercise | 0.00 | 27,861 | 0 | 170,023 | Jun 30 |
| Krishnan K Ranga | Director | Apr 22 '26 | Option Exercise | 0.00 | 46,950 | 0 | 156,093 | Apr 22 |
| Pitt Justin D | Pres,Chief Legal&Admin Officer | Mar 01 '26 | Option Exercise | 0.00 | 30,000 | 0 | 272,672 | Mar 03 |
| Johnson Jason K | EVP & CFO | Mar 01 '26 | Option Exercise | 0.00 | 30,000 | 0 | 202,049 | Mar 03 |
| HAMMONS KEVIN J | CEO | Mar 01 '26 | Option Exercise | 0.00 | 156,240 | 0 | 792,441 | Mar 03 |
| Williams Hubert James | Director | Mar 01 '26 | Option Exercise | 0.00 | 50,595 | 0 | 211,863 | Mar 03 |
| Hirsch Elizabeth T | Director | Mar 01 '26 | Option Exercise | 0.00 | 50,595 | 0 | 162,059 | Mar 03 |
| FRY JOHN A | Director | Mar 01 '26 | Option Exercise | 0.00 | 50,595 | 0 | 268,966 | Mar 03 |
| Ely James S. III | Director | Mar 01 '26 | Option Exercise | 0.00 | 50,595 | 0 | 412,876 | Mar 03 |
| DINKINS MICHAEL | Director | Mar 01 '26 | Option Exercise | 0.00 | 30,662 | 0 | 225,882 | Mar 03 |
| CLERICO JOHN A | Director | Mar 01 '26 | Option Exercise | 0.00 | 50,595 | 0 | 368,763 | Mar 03 |
| Brooks Susan W | Director | Mar 01 '26 | Option Exercise | 0.00 | 50,595 | 0 | 108,695 | Mar 03 |
| STOCKTON KEVIN A | EVP, Operations & Development | Mar 01 '26 | Option Exercise | 0.00 | 50,000 | 0 | 213,863 | Mar 03 |
| Ely James S. III | Director | Dec 31 '25 | Option Exercise | 0.00 | 2,882 | 0 | 362,281 | Dec 31 |